Combination of a PD-1 antagonist and eribulin for treating cancer
AssigneesEisai R&D Management Co., Ltd., Merck Sharp & Dohme Corp.
InventorsJunji Matsui, Gursel Aktan, Vassiliki Karantza, RuiRong Yuan, Yasuhiro Funahashi, Erhan Berrak
Life of this patent
Estimating the term…
Abstract
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and eribulin or a pharmaceutically acceptable salt thereof, and the use of the combination therapies for the treatment of cancer.
Claims6
A method for treating triple negative breast cancer in an individual comprising administering to the individual a combination therapy which comprises (i) an antagonist of a Programmed Death 1 protein (PD-1), wherein the PD-1 antagonist is pembrolizumab, and (ii) eribulin or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.